Humana Inc. (HUM) Earns Neutral Rating from Susquehanna
Humana Inc. (NYSE:HUM)‘s stock had its “neutral” rating reissued by investment analysts at Susquehanna in a note issued to investors on Thursday. They presently have a $180.00 price target on the insurance provider’s stock. Susquehanna’s price objective would suggest a potential upside of 6.21% from the company’s current price.
Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald reissued a “buy” rating on shares of Humana in a research report on Saturday, July 9th. Royal Bank Of Canada cut their target price on shares of Humana from $222.00 to $217.00 and set a “sector perform” rating on the stock in a research report on Thursday. RBC Capital Markets reissued a “buy” rating and set a $224.00 target price (up previously from $220.00) on shares of Humana in a research report on Friday, July 22nd. Credit Suisse Group AG reissued a “hold” rating and set a $188.00 target price on shares of Humana in a research report on Tuesday, September 13th. Finally, Jefferies Group reissued a “buy” rating and set a $220.00 target price (up previously from $210.00) on shares of Humana in a research report on Monday, July 25th. Seven research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $200.50.
Shares of Humana (NYSE:HUM) traded up 0.62% during midday trading on Thursday, hitting $169.48. 1,635,324 shares of the stock traded hands. The firm has a market capitalization of $25.26 billion, a PE ratio of 26.04 and a beta of 0.90. Humana has a 52 week low of $150.00 and a 52 week high of $191.65. The company’s 50-day moving average is $176.12 and its 200 day moving average is $175.83.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/humana-inc-hum-earns-neutral-rating-from-susquehanna.html
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 3rd. The insurance provider reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.23 by $0.07. Humana had a net margin of 1.76% and a return on equity of 11.11%. The business earned $14 billion during the quarter, compared to analyst estimates of $13.59 billion. During the same quarter last year, the business earned $1.67 earnings per share. Humana’s quarterly revenue was up 2.0% compared to the same quarter last year. Analysts anticipate that Humana will post $9.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Thursday, October 13th will be issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date is Tuesday, October 11th. Humana’s payout ratio is 18.18%.
A number of hedge funds and other institutional investors have recently bought and sold shares of HUM. Capstone Asset Management Co. raised its stake in shares of Humana by 0.9% in the third quarter. Capstone Asset Management Co. now owns 13,373 shares of the insurance provider’s stock worth $2,366,000 after buying an additional 124 shares during the period. Creative Planning raised its stake in shares of Humana by 9.4% in the third quarter. Creative Planning now owns 7,174 shares of the insurance provider’s stock worth $1,269,000 after buying an additional 619 shares during the period. Daiwa SB Investments Ltd. raised its stake in shares of Humana by 1.4% in the third quarter. Daiwa SB Investments Ltd. now owns 730 shares of the insurance provider’s stock worth $129,000 after buying an additional 10 shares during the period. Fulton Bank N.A. acquired a new stake in shares of Humana during the third quarter worth about $229,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Humana by 86.3% in the third quarter. BNP Paribas Arbitrage SA now owns 20,317 shares of the insurance provider’s stock worth $3,594,000 after buying an additional 9,414 shares during the period. 93.24% of the stock is currently owned by institutional investors.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.